Literature DB >> 21543173

Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors.

Taiichi Saito1, Fumiyuki Yamasaki, Yoshinori Kajiwara, Nobukazu Abe, Yuji Akiyama, Takako Kakuda, Yukio Takeshima, Kazuhiko Sugiyama, Yoshikazu Okada, Kaoru Kurisu.   

Abstract

OBJECTIVE: The differentiation of oligodendroglial tumors from astrocytic tumors is important clinically, because oligodendroglial tumors are more chemosensitive than astrocytic tumors. This study was designed to clarify the usefulness of 3T MR perfusion imaging (PWI) in the histopathological differentiation between astrocytic and oligodendroglial tumors. This is because there is a growing interest in the diagnostic performance of 3T MR imaging, which has the advantages of a higher signal-to-noise ratio (SNR) and greater spatial and temporal resolution.
MATERIALS AND METHODS: This study retrospectively included 24 consecutive patients with supratentorial, WHO grade II and III astrocytic and oligodendroglial tumors (7 astrocytic, 10 oligoastrocytic, and 7 oligodendroglial tumors) that were newly diagnosed and resected between November 2006 and December 2009 at Hiroshima University Hospital. These patients underwent dynamic susceptibility contrast-enhanced (DSC) PWI relative cerebral blood volume (rCBV) measurements before treatment. Astrocytic tumors were designated as the astrocytic group, and oligoastrocytic and oligodendroglial tumors as the oligodendroglial group. The regions of interest with the maximum rCBV values within the tumors were normalized relative to the contra-lateral white matter (rCBVmax).
RESULTS: The average rCBVmax of astrocytic tumors (2.01±0.68) was significantly lower than that of the oligoastrocytic (4.60±1.05) and oligodendroglial tumors (6.17±0.867) (P<0.0001). A cut-off value of 3.0 allowed to differentiate the oligodendroglial group from the astrocytic group at 100% sensitivity and 87.5% specificity.
CONCLUSION: The rCBVmax values obtained from 3T MR PWI may be useful as an adjunct to the postoperative histopathological diagnosis of glioma patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21543173     DOI: 10.1016/j.ejrad.2011.04.009

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  21 in total

1.  Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.

Authors:  K M Schmainda; M A Prah; S D Rand; Y Liu; B Logan; M Muzi; S D Rane; X Da; Y-F Yen; J Kalpathy-Cramer; T L Chenevert; B Hoff; B Ross; Y Cao; M P Aryal; B Erickson; P Korfiatis; T Dondlinger; L Bell; L Hu; P E Kinahan; C C Quarles
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-24       Impact factor: 3.825

2.  [Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI].

Authors:  A Radbruch; E Hattingen
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

Review 3.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

4.  Whole-tumor histogram analysis of the cerebral blood volume map: tumor volume defined by 11C-methionine positron emission tomography image improves the diagnostic accuracy of cerebral glioma grading.

Authors:  Rongli Wu; Yoshiyuki Watanabe; Atsuko Arisawa; Hiroto Takahashi; Hisashi Tanaka; Yasunori Fujimoto; Tadashi Watabe; Kayako Isohashi; Jun Hatazawa; Noriyuki Tomiyama
Journal:  Jpn J Radiol       Date:  2017-09-06       Impact factor: 2.374

Review 5.  Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis.

Authors:  Anna F Delgado; Alberto F Delgado
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-18       Impact factor: 3.825

6.  Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas.

Authors:  Julio Arevalo-Perez; Kyung K Peck; Robert J Young; Andrei I Holodny; Sasan Karimi; John K Lyo
Journal:  J Neuroimaging       Date:  2015-04-13       Impact factor: 2.486

7.  Characteristics of time-activity curves obtained from dynamic 11C-methionine PET in common primary brain tumors.

Authors:  Yuichi Nomura; Yoshitaka Asano; Jun Shinoda; Hirohito Yano; Yuka Ikegame; Tomohiro Kawasaki; Noriyuki Nakayama; Takashi Maruyama; Yoshihiro Muragaki; Toru Iwama
Journal:  J Neurooncol       Date:  2018-03-21       Impact factor: 4.130

8.  Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM.

Authors:  Emma Essock-Burns; Joanna J Phillips; Annette M Molinaro; Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2012-12-19       Impact factor: 4.813

9.  Comparison of the Diagnostic Accuracy of DSC- and Dynamic Contrast-Enhanced MRI in the Preoperative Grading of Astrocytomas.

Authors:  T B Nguyen; G O Cron; K Perdrizet; K Bezzina; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J Sinclair; R E Thornhill; C Foottit; B Zanette; I G Cameron
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-30       Impact factor: 3.825

10.  Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.

Authors:  Otto M Henriksen; Vibeke A Larsen; Aida Muhic; Adam E Hansen; Henrik B W Larsson; Hans S Poulsen; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.